$0.00
0.00%
NYSE, Mon, Nov 25 2024
ISIN
US46185L1035
Symbol
NVTA

Invitae Corp. Stock price

$0.00
+0.00 0.00% 1M
-0.00 62.50% 6M
-0.63 99.95% YTD
-0.53 99.94% 1Y
-18.18 100.00% 3Y
-20.57 100.00% 5Y
-17.05 100.00% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US46185L1035
Symbol
NVTA
Sector

Key metrics

Market capitalization $90.00k
Enterprise Value $1.25b
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.60
P/S ratio (TTM) P/S ratio 0.00
P/B ratio (TTM) P/B ratio 0.00
Revenue growth (TTM) Revenue growth -7.38%
Revenue (TTM) Revenue $481.58m
EBIT (operating result TTM) EBIT $-498.20m
Free Cash Flow (TTM) Free Cash Flow $-247.82m
Cash position $254.57m
EPS (TTM) EPS $-5.38
P/E forward 0.00
P/S forward 0.00
EV/Sales forward 2.50
Short interest 26.20%
Show more

Is Invitae Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Invitae Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Invitae Corp.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Invitae Corp.:

Hold
100%

Financial data from Invitae Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
482 482
7% 7%
100%
- Direct Costs 351 351
17% 17%
73%
131 131
34% 34%
27%
- Selling and Administrative Expenses 231 231
25% 25%
48%
- Research and Development Expense 252 252
42% 42%
52%
-352 -352
46% 46%
-73%
- Depreciation and Amortization 147 147
19% 19%
30%
EBIT (Operating Income) EBIT -498 -498
35% 35%
-103%
Net Profit -1,441 -1,441
55% 55%
-299%

In millions USD.

Don't miss a Thing! We will send you all news about Invitae Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Head office United States
CEO Kenneth Knight
Founded 2010
Website www.invitae.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today